At a time when striving for a longer, but above all healthier life, is becoming more and more important, companies such as MoleQlar Paving the way for the future of the healthcare industry. With their recently successfully completed seed financing and the acquisition of epiqMAX, they have taken a remarkable step towards innovative and personalized longevity solutions.

‍

‍

A pioneer in healthcare solutions

The Berlin-based company MoleQlar focuses on developing scientifically based products and solutions that can combat aging on a molecular level. The recent acquisition of EpiqMax (now MoleQlar Analytics), a company specialized in epigenetics and proteome analysis, promises synergies that will drive personalization in the Longevity sector.

‍

‍

Proteome-based saliva test: making progress measurable

In addition to focusing on molecular Hallmarks of Aging The company attaches particular importance to making progress tangible for people. This is where the future proteome-based saliva test from MoleQlar Analytics comes into play, which allows customers to directly track and measure their molecular changes. This test opens up many new options for personalizing Longevity interventions and is intended to provide a comprehensive snapshot and the possibility of precise progress checks.

‍

‍

Cash flow for innovation and growth

The fresh capital from the financing round will be used to further develop this test and develop new formulations and marketing measures. This focus on innovation and public education demonstrates MoleQlar's commitment to accessible and evidence-based healthcare.

‍

With the mission of bringing scientific knowledge from the laboratory into everyday life, MoleQlar has developed into a leading company for longevity solutions in German-speaking countries since its founding in 2020. The clear and understandable approach to dietary supplements and health tests sets the company apart and enables people to actively participate in their own health.

‍

‍

Founder engagement and future visions

The founders of MoleQlar, Maximilian Griessinger, Mario Gietl and Clemens Klingler, emphasize that this investment will accelerate research and development activities, expand market presence and maintain the commitment to improving the quality of life and health of as many people as possible.

‍

‍

The future of MoleQlar promises to build a bridge between advanced scientific knowledge and practical application in everyday life, which could play a decisive role in how we understand and ultimately live health.

‍

Overall, the dynamics of MoleQlar and its connection to epigenetics and proteome analysis of how companies can help expand the frontiers of healthcare. The resulting opportunities for the future of healthy aging are promising and could bring us one step closer to a healthier and longer life.

‍

https://www.moleqlar.de